|
1
|
Lv ZC, Fan YS, Chen HB and Zhao DW:
Investigation of microRNA-155 as a serum diagnostic and prognostic
biomarker for colorectal cancer. Tumour Biol. 36:1619–1625. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eslamizadeh S, Heidari M, Agah S,
Faghihloo E, Ghazi H, Mirzaei A and Akbari A: The role of microRNA
signature as diagnostic biomarkers in different clinical stages of
colorectal cancer. Cell J. 20:220–230. 2018.PubMed/NCBI
|
|
3
|
Fabian P and Němeček R: Prediction of EGFR
blockade responses in metastatic colorectal carcinoma. Cesk Patol.
54:17–21. 2018.(In Czech). PubMed/NCBI
|
|
4
|
Ramon L, David C, Fontaine K, Lallet E,
Marcaillou C, Martin-Lannerée S, Decaulne V, Vazart C, Gélibert AH,
Abdelali RB, et al: Technical validation of a reverse-transcription
quantitative polymerase chain reaction in vitro diagnostic test for
the determination of miR-31-3p expression levels in formalin-fixed
paraffin-embedded metastatic colorectal cancer tumor specimens.
Biomark Insights. 13:11772719187633572018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Heublein S, Albertsmeier M, Pfeifer D,
Loehrs L, Bazhin AV, Kirchner T, Werner J, Neumann J and Angele MK:
Association of differential miRNA expression with hepatic vs.
peritoneal metastatic spread in colorectal cancer. BMC Cancer.
18:2012018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bandres E, Agirre X, Bitarte N, Ramirez N,
Zarate R, Roman-Gomez J, Prosper F and Garcia-Foncillas J:
Epigenetic regulation of microRNA expression in colorectal cancer.
Int J Cancer. 125:2737–2743. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lundberg IV, Wikberg ML, Ljuslinder I, Li
X, Myte R, Zingmark C, Löfgren-Burström A, Edin S and Palmqvist R:
MicroRNA expression in KRAS- and BRAF-mutated colorectal cancers.
Anticancer Res. 38:677–683. 2018.PubMed/NCBI
|
|
8
|
Pugh S, Thiébaut R, Bridgewater J, Grisoni
ML, Moutasim K, Rousseau F, Thomas GJ, Griffiths G, Liebaert F,
Primrose J, et al: Association between miR-31-3p expression and
cetuximab efficacy in patients with KRAS wild-type metastatic
colorectal cancer: A post-hoc analysis of the New EPOC trial.
Oncotarget. 8:93856–93866. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang YN, Chen ZH and Chen WC: Novel
circulating microRNAs expression profile in colon cancer: A pilot
study. Eur J Med Res. 22:512017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Takahashi H, Takahashi M, Ohnuma S, Unno
M, Yoshino Y, Ouchi K, Takahashi S, Yamada Y, Shimodaira H and
Ishioka C: microRNA-193a-3p is specifically down-regulated and acts
as a tumor suppressor in BRAF-mutated colorectal cancer. BMC
Cancer. 17:7232017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li J, Li X, Cen C, Ai X, Lin C and Hu G:
The long non-coding RNA ENST00000547547 reduces 5-fluorouracil
resistance of colorectal cancer cells via competitive binding to
microRNA-31. Oncol Rep. 39:217–226. 2018.PubMed/NCBI
|
|
13
|
Tian Y, Ma X, Lv C, Sheng X, Li X, Zhao R,
Song Y, Andl T, Plikus MV, Sun J, et al: Stress responsive miR-31
is a major modulator of mouse intestinal stem cells during
regeneration and tumorigenesis. eLife. 6:538–540. 2017. View Article : Google Scholar
|
|
14
|
Wang H, Luo J, Liu C, Niu H, Wang J, Liu
Q, Zhao Z, Xu H, Ding Y, Sun J, et al: Investigating microRNA and
transcription factor co-regulatory networks in colorectal cancer.
BMC Bioinformatics. 18:3882017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yuan Z, Baker K, Redman MW, Wang L, Adams
SV, Yu M, Dickinson B, Makar K, Ulrich N, Böhm J, et al: Dynamic
plasma microRNAs are biomarkers for prognosis and early detection
of recurrence in colorectal cancer. Br J Cancer. 117:1202–1210.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu X, Pan B, Sun L, Chen X, Zeng K, Hu X,
Xu T, Xu M and Wang S: Circulating exosomal miR-27a and miR-130a
act as novel diagnostic and prognostic biomarkers of colorectal
cancer. Cancer Epidemiol Biomarkers Prev. 27:746–754. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liang J, Tang J, Shi H, Li H, Zhen T, Duan
J, Kang L, Zhang F, Dong Y and Han A: miR-27a-3p targeting RXRα
promotes colorectal cancer progression by activating Wnt/β-catenin
pathway. Oncotarget. 8:82991–83008. 2017.PubMed/NCBI
|
|
18
|
Chen M, Fang W, Wu X, Bian S, Chen G, Lu L
and Weng Y: Distinct effects of rs895819 on risk of different
cancers: An update meta-analysis. Oncotarget. 8:75336–75349.
2017.PubMed/NCBI
|
|
19
|
Xu Q, Tong JL, Zhang CP, Xiao Q, Lin XL
and Xiao XY: miR-27a induced by colon cancer cells in HLECs
promotes lymphangiogenesis by targeting SMAD4. PLoS One.
12:e01867182017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ba S, Xuan Y, Long ZW, Chen HY and Zheng
SS: MicroRNA-27a promotes the proliferation and invasiveness of
colon cancer cells by targeting SFRP1 through the Wnt/β-catenin
signaling pathway. Cell Physiol Biochem. 42:1920–1933. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao Y, Ting KK, Li J, Cogger VC, Chen J,
Johansson-Percival A, Ngiow SF, Holst J, Grau G, Goel S, et al:
Targeting vascular endothelial-cadherin in tumor-associated blood
vessels promotes T-cell-mediated immunotherapy. Cancer Res.
77:4434–4447. 2017. View Article : Google Scholar : PubMed/NCBI
|
